Oncology Institute Inc (TOI) — Titan Protect Analysis

TOI

Oncology Institute Inc

Healthcare · ·

$4.87

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$434M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-27.13

Based on estimated future earnings — lower means cheaper

Rev Growth

+41.2%

Year-over-year revenue change

Profit Margin

-8.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.50

+54% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Oncology Institute Inc

The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support servi

https://theoncologyinstitute.com

Country: United States Employees: 641 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.624

Excellent risk-adjusted returns

Kelly Fraction

0.0902

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.968

Returns exceed worst-case losses — strong risk profile

Annual Return

226.9%

Historical annualised return based on price data

Max Drawdown

-76.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

117

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.36

Very low correlation to market moves

52W High

$4.90

1% below the year high

52W Low

$2.02

142% above the year low

Avg Volume

1,855,949

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.35

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

15.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-4.4%

Profit from core operations before interest and tax

Free Cash Flow

$-15,312,625

Negative — the business is spending more than it generates

Revenue (TTM)

$546M

Total revenue over the last 12 months

Net Income

$-36,324,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$8.00

Target Median

$7.50

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go